Compare Sana Biotechnology Inc (SANA) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Victoria's Secret & Co — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Victoria's Secret & Co trades at $82.86 (market cap $6.91B). The key difference: Victoria's Secret & Co is far larger — about 8.3× Sana Biotechnology Inc's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Victoria's Secret & Co for 34 Days on average.
| SANA | VSXY | |
|---|---|---|
Market Cap | $836.71M | $6.91B |
Volume | 4,507,444 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $99.97 |
52-Week Low | $2.68 | $28.25 |
Typical Hold Time | 23 Days | 34 Days |
Enterprise Value | $749.96M | $9.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Victoria's Secret (VSXY) trades at $82.87, down 3.4% on the day, but maintains strong analyst support with a 60% buy rating and $86.80 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q4 2025 and Q1-Q2 2026, while fundamentals reveal improving profitability with 39.57% gross margins and 45.27% ROE. Recent news highlights brand momentum through fashion show expansions and omnichannel retail growth.
The outlook remains positive with projected 2026 revenue growth to $6.9B and net income of $378M, though risks include elevated valuation metrics (P/E 19.33) and competitive pressures. Institutional interest is strengthening with recent investments from Tidal Investments and California State Teachers Retirement System, supporting the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
